Adlon is dedicated to improving the lives of patients with ADHD, and will provide support for studies that contribute to a better understating of the condition in these individuals.
Research proposals for this funding will be accepted starting TODAY and through June 14, 2019.
Clinical research conducted under Adlon's IIR programme will be developed and implemented entirely by researchers in the US, with funding provided by Adlon.
The design and the results of these studies will be made public through various channels including scientific publications or public websites.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder and related disorders.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval